Skip to main content
SpringerLink
Log in

Correlation of apolipoprotein A-I kinetics with survival and response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The aim of this study was to determine whether apolipoprotein A-I (ApoA-I) kinetics predict the overall survival in patients with advanced-stage non-small cell lung cancer (NSCLC) during platinum-based first-line therapy. A total of 125 NSCLC patients from January 2008 to September 2014 were retrospectively reviewed. Serum ApoA-I level was measured at baseline and thereafter at the start of each palliative chemotherapy cycle for all patients. Patients were divided into four groups according to ApoA-I kinetics. Patients whose ApoA-I ≥ 1.01 g/L and never decreased during treatment, patients whose ApoA-I ≥ 1.01 g/L and decreased (ApoA-I < 1.01 g/L) at least one time during treatment, patients whose ApoA-I < 1.01 g/L and normalized (ApoA-I ≥ 1.01) at least one time during treatment, and patients whose ApoA-I < 1.01 g/L and never normalized during treatment were assigned to non-decreased, decreased, normalized, and non-normalized ApoA-I groups, respectively. Overall survival rates were significantly different between the four groups, with 2-year survival rates of 88.6 and 17.5 % for the non-decreased and the decreased ApoA-I groups, respectively, and none survived 2 years later in the normalized and the non-normalized ApoA-I groups. When compared with the non-decreased group, the hazard ratios of death were 0.05, 0.44, and 1.73 in the normalized, decreased, and non-normalized groups, respectively (P < 0.001). Normalization of ApoA-I was associated with a low risk of progression, whereas patients with a decreased level of ApoA-I showed a progression of disease in most cases. ApoA-I can be a novel, widely available biomarker for patients with NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Delbaldo C, Michiels S, Rolland E, Syz N, Soria JC, Le Chevalier T, et al. Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev. 2007;(4):CD004569. doi:10.1002/14651858.CD004569.pub3.

  2. Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest J. 2006;130(4):1211–9.

    Article  CAS  Google Scholar 

  3. Camps C, Sirera R, Iranzo V, Tarón M, Rosell R. Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy. Clin Lung Cancer. 2007;8(6):369–75.

    Article  CAS  PubMed  Google Scholar 

  4. Brower V. Biomarker studies abound for early detection of lung cancer. J Natl Cancer Inst. 2009;101(1):11–3.

    Article  CAS  PubMed  Google Scholar 

  5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348(17):1625–38.

    Article  PubMed  Google Scholar 

  6. Michalaki V, Koutroulis G, Syrigos K, Piperi C, Kalofoutis A. Evaluation of serum lipids and high-density lipoprotein subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer. Mol Cell Biochem. 2005;268(1–2):19–24.

    Article  CAS  PubMed  Google Scholar 

  7. van Duijnhoven FJ, Bueno-De-Mesquita HB, Calligaro M, Jenab M, Pischon T, Jansen EH, et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut. 2011;60:1094–102.

    Article  PubMed  Google Scholar 

  8. Tamura T, Inagawa S, Hisakura K, Enomoto T, Ohkohchi N. Evaluation of serum high-density lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients. J Gastroenterol Hepatol. 2012;27(10):1635–40.

    Article  CAS  PubMed  Google Scholar 

  9. Chi PD, Liu W, Chen H, Zhang JP, Lin Y, Zheng X, et al. High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with c-reactive protein level in non-small cell lung carcinoma. PLoS One. 2014;9(3):e91080.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Brewer HJ, Fairwell T, LaRue A, Ronan R, Houser A, Bronzert TJ. The amino acid sequence of human APOA-I, an apolipoprotein isolated from high density lipoproteins. Biochem Biophys Res Commun. 1978;80(3):623–30.

    Article  CAS  PubMed  Google Scholar 

  11. Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I. J Clin Invest. 1988;82(3):803–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Chang SJ, Hou MF, Tsai SM, Wu SH, Ann Hou L, Ma H, et al. The association between lipid profiles and breast cancer among Taiwanese women. Clin Chem Lab Med. 2007;45(9):1219–23.

    Article  CAS  PubMed  Google Scholar 

  13. Lane DM, Boatman KK, McConathy WJ. Serum lipids and apolipoproteins in women with breast masses. Breast Cancer Res Treat. 1995;34(2):161–9.

    Article  CAS  PubMed  Google Scholar 

  14. Ehmann M, Felix K, Hartmann D, Schnölzer M, Nees M, Vorderwülbecke S, et al. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas. 2007;34(2):205–14.

    Article  CAS  PubMed  Google Scholar 

  15. Zhang Z, Bast RJ, Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004;64(16):5882–90.

    Article  CAS  PubMed  Google Scholar 

  16. Simpson DC, Kabyemela E, Muehlenbachs A, Ogata Y, Mutabingwa TK, Duffy PE, et al. Plasma levels of apolipoprotein A1 in malaria exposed primigravidae are associated with severe anemia. PLoS One. 2010;5(1):e8822.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Jiang R, Yang ZH, Luo DH, Guo L, Sun R, Chen QY, et al. Elevated apolipoprotein AI levels are associated with favorable prognosis in metastatic nasopharyngeal carcinoma. Med Oncol. 2014;31(8):1–9.

    Google Scholar 

  18. Charet JC, Watine J, Marre A, Charet P. Valeur pronostique des taux sériques de cholestérol et de l’apolipoprotéine A1 dans le cancer pulmonaire. Ann Biol Clin. 1997;55(1):52–60.

    CAS  Google Scholar 

  19. Xia WX, Zhang HB, Shi JL, Lu X, Wang L, Ye YF, et al. A prognostic model predicts the risk of distant metastasis and death for patients with nasopharyngeal carcinoma based on pre-treatment serum C-reactive protein and N-classification. Eur J Cancer. 2013;49(9):2152–60.

    Article  CAS  PubMed  Google Scholar 

  20. Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai YH, Chen YM, et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer. 2013;132(9):1977–85.

    Article  CAS  PubMed  Google Scholar 

  21. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–14.

    Article  CAS  PubMed  Google Scholar 

  22. Ljungberg B, Grankvist K, Rasmuson T. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer. 1997;33(11):1794–8.

    Article  CAS  PubMed  Google Scholar 

  23. Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kurzrock R. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma. 1998;30(5–6):563–71.

    CAS  PubMed  Google Scholar 

  24. Liao WC, Lin JT, Wu CY, Huang SP, Lin MT, Wu ASH, et al. Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcimoma. Clin Cancer Res. 2008;14(2):428–34.

    Article  CAS  PubMed  Google Scholar 

  25. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res. 2000;6(7):2702–6.

    CAS  PubMed  Google Scholar 

  26. De Vita F, Romano C, Orditura M, Galizia G, Martinelli E, Lieto E, et al. Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res. 2001;21(1):45–52.

    Article  PubMed  Google Scholar 

  27. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003;103(5):642–6.

    Article  CAS  PubMed  Google Scholar 

  28. Martín F, Santolaria F, Batista N, Milena A, González-Reimers E, Brito MJ, et al. Cytokine levels (IL-6 and IFN-c) acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine. 1999;11(1):80–6.

    Article  PubMed  Google Scholar 

  29. Songür N, Kuru B, Kalkan F, Ozdilekcan C, Çakmak H, Hizel N. Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori. 2004;90(2):196–200.

    PubMed  Google Scholar 

  30. Crowl RM, Stoller TJ, Conroy RR, Stoner CR. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J Biol Chem. 1991;266(4):2647–51.

    CAS  PubMed  Google Scholar 

  31. Tietge UJ, Maugeais C, Cain W, Grass D, Glick JM, de Beer F, et al. Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J Biol Chem. 2000;275(14):10077–84.

    Article  CAS  PubMed  Google Scholar 

  32. Tietge UJ, Maugeais C, Lund-Katz S, Grass D, Rader DJ. Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice. Arterioscler Thromb Vasc Biol. 2002;22(7):1213–8.

    Article  CAS  PubMed  Google Scholar 

  33. Zamanian-Daryoush M, Lindner D, Wang Z, Buffa J, Klipfell E, et al. The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol Chem. 2013;288(29):21237–52.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank Yi-Chen Li, pharmacologist, the Affiliated Drum Tower Hospital of Nanjing University Medical College, Dan-Li Zhou, for her help with the patient registry.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210009, China

    Ting Cheng, Xin Dai, Dan-Li Zhou & Yang Lv

  2. Division of Respiratory Medicine, Department of Respiration, The Affiliated Drum Tower Hospital of Nanjing University Medical College, Nanjing University Medical School, Nanjing, 210008, China

    Ting Cheng & Li-Yun Miao

Authors
  1. Ting Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xin Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dan-Li Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yang Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Li-Yun Miao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Li-Yun Miao.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cheng, T., Dai, X., Zhou, DL. et al. Correlation of apolipoprotein A-I kinetics with survival and response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Med Oncol 32, 407 (2015). https://doi.org/10.1007/s12032-014-0407-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0407-8

Keywords

Search

Navigation